• February 19, 2021  

    Renal Cell Carcinoma—An Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    There are now many precision oncology treatments for the most common type of kidney cancer, renal cell carcinoma, which represents about 3% of all potentially lethal cancers in America. This summary from Medscape details all the traditional treatment approaches, as well as newer considerations.

    .

  • February 2, 2021  

    How an Expert Would Manage Her Own Advanced Ovarian Cancer

    With: Summer Dewdney, MD

    Cancer patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Summer Dewdney, MD, how she would handle her own diagnosis of advanced ovarian cancer. Dr. Dewdney is Director of the Division of Gynecologic Oncology at Rush University Medical Center in Chicago, Illinois. Curious Dr. George: You are an expert clinical oncologist treating patients… Read more »

  • December 18, 2020  

    How an Expert Would Manage Her Own Advanced Colorectal Cancer

    With: Christina Wu, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Cancer Commons Expert Physician Advisor Christina Wu, MD, how she would handle her own diagnosis of metastatic colorectal cancer. Dr. Wu is Associate Professor of Hematology/Oncology and Associate Division Director of Medical Oncology at Winship Cancer Institute of Emory… Read more »

  • December 3, 2020  

    A Phase I Study of Telomelysin Added to Chemoradiation for Patients with Advanced Inoperable Esophageal Cancer Bookmark

    George Lundberg, MD

    Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

    .

  • December 3, 2020  

    Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark

    George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  • December 3, 2020  

    Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark

    George Lundberg, MD

    A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

    .

  • November 24, 2020  

    Two New Treatments Approved For Advanced Prostate Cancer Bookmark

    George Lundberg, MD

    A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.

    .

  • November 24, 2020  

    Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial Bookmark

    George Lundberg, MD

    A story from Immuno-Oncology News covers new results from a phase 1 clinical trial that indicate promising safety and early efficacy of a treatment that combines the drug Keytruda and an experimental cancer vaccine for people with advanced melanoma.

    .

  • November 24, 2020  

    Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Bookmark

    George Lundberg, MD

    This scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.

    .

  • November 6, 2020  

    What’s New in Treatments that Target the MAPK Pathway in Cancer?

    Emma Shtivelman, PhD

    If you are learning about treatment options for your or your loved one’s cancer, you may have heard of the MAPK pathway. This biological feature of human cells has become an important target of numerous drugs to treat cancer. Read on to learn more about the MAPK pathway and the current status of treatments that target it. What is the MAPK pathway? The mitogen-activated… Read more »